Feasibility and safety of repeated transarterial chemoembolization using miriplatin-lipiodol suspension for hepatocellular carcinoma

Tomohiro Matsumoto; Hitoshi Ichikawa; Jin Imai; Toshihiko Hayashi; Kosuke Tomita; Takahiko Mine; Seiichiro Kojima; Norihito Watanabe; Terumitsu Hasebe

doi:10.21873/anticanres.11678

Feasibility and safety of repeated transarterial chemoembolization using miriplatin-lipiodol suspension for hepatocellular carcinoma

Tomohiro Matsumoto, Hitoshi Ichikawa, Jin Imai, Toshihiko Hayashi, Kosuke Tomita, Takahiko Mine, Seiichiro Kojima, Norihito Watanabe, Terumitsu Hasebe

Research output: Contribution to journal › Article › peer-review

4 Citations (Scopus)

Abstract

Aim: To retrospectively evaluate the feasibility and safety of repeated transarterial chemoembolization (TACE) three or more times using miriplatin-lipiodol (MLPD) suspension (repeated M-LPD TACE) for hepatocellular carcinoma (HCC). Patients and Methods: Sixteen patients who underwent repeated M-LPD TACE were examined. Total dose of miriplatin, lipiodol and porous gelatin sponge particles and adverse events of the first and last M-LPD TACE were evaluated. Results: The mean±standard deviation (SD) of the total number of M-LPD TACE per patient was 3.7±1.1. The mean±SD dose of total miriplatin, lipiodol and porous gelatin sponge particles per patient was 303±103 mg, 21±7.3 ml and 84±57 mg, respectively. There were no significant differences in any adverse events between the first and last M-LPD TACE. Conclusion: Repeated M-LPD TACE for HCC is feasible and safe in selected patients.

Original language	English
Pages (from-to)	3183-3187
Number of pages	5
Journal	Anticancer research
Volume	37
Issue number	6
DOIs	https://doi.org/10.21873/anticanres.11678
Publication status	Published - 2017 Jun
Externally published	Yes

Keywords

Hepatocellular carcinoma
Miriplatin
Transarterial chemoembolization

ASJC Scopus subject areas

Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.21873/anticanres.11678

Cite this

@article{5f85fdbd010b4488879359a7fb9aa35d,

title = "Feasibility and safety of repeated transarterial chemoembolization using miriplatin-lipiodol suspension for hepatocellular carcinoma",

abstract = "Aim: To retrospectively evaluate the feasibility and safety of repeated transarterial chemoembolization (TACE) three or more times using miriplatin-lipiodol (MLPD) suspension (repeated M-LPD TACE) for hepatocellular carcinoma (HCC). Patients and Methods: Sixteen patients who underwent repeated M-LPD TACE were examined. Total dose of miriplatin, lipiodol and porous gelatin sponge particles and adverse events of the first and last M-LPD TACE were evaluated. Results: The mean±standard deviation (SD) of the total number of M-LPD TACE per patient was 3.7±1.1. The mean±SD dose of total miriplatin, lipiodol and porous gelatin sponge particles per patient was 303±103 mg, 21±7.3 ml and 84±57 mg, respectively. There were no significant differences in any adverse events between the first and last M-LPD TACE. Conclusion: Repeated M-LPD TACE for HCC is feasible and safe in selected patients.",

keywords = "Hepatocellular carcinoma, Miriplatin, Transarterial chemoembolization",

author = "Tomohiro Matsumoto and Hitoshi Ichikawa and Jin Imai and Toshihiko Hayashi and Kosuke Tomita and Takahiko Mine and Seiichiro Kojima and Norihito Watanabe and Terumitsu Hasebe",

year = "2017",

month = jun,

doi = "10.21873/anticanres.11678",

language = "English",

volume = "37",

pages = "3183--3187",

journal = "Anticancer Research",

issn = "0250-7005",

publisher = "International Institute of Anticancer Research",

number = "6",

}

TY - JOUR

T1 - Feasibility and safety of repeated transarterial chemoembolization using miriplatin-lipiodol suspension for hepatocellular carcinoma

AU - Matsumoto, Tomohiro

AU - Ichikawa, Hitoshi

AU - Imai, Jin

AU - Hayashi, Toshihiko

AU - Tomita, Kosuke

AU - Mine, Takahiko

AU - Kojima, Seiichiro

AU - Watanabe, Norihito

AU - Hasebe, Terumitsu

PY - 2017/6

Y1 - 2017/6

N2 - Aim: To retrospectively evaluate the feasibility and safety of repeated transarterial chemoembolization (TACE) three or more times using miriplatin-lipiodol (MLPD) suspension (repeated M-LPD TACE) for hepatocellular carcinoma (HCC). Patients and Methods: Sixteen patients who underwent repeated M-LPD TACE were examined. Total dose of miriplatin, lipiodol and porous gelatin sponge particles and adverse events of the first and last M-LPD TACE were evaluated. Results: The mean±standard deviation (SD) of the total number of M-LPD TACE per patient was 3.7±1.1. The mean±SD dose of total miriplatin, lipiodol and porous gelatin sponge particles per patient was 303±103 mg, 21±7.3 ml and 84±57 mg, respectively. There were no significant differences in any adverse events between the first and last M-LPD TACE. Conclusion: Repeated M-LPD TACE for HCC is feasible and safe in selected patients.

AB - Aim: To retrospectively evaluate the feasibility and safety of repeated transarterial chemoembolization (TACE) three or more times using miriplatin-lipiodol (MLPD) suspension (repeated M-LPD TACE) for hepatocellular carcinoma (HCC). Patients and Methods: Sixteen patients who underwent repeated M-LPD TACE were examined. Total dose of miriplatin, lipiodol and porous gelatin sponge particles and adverse events of the first and last M-LPD TACE were evaluated. Results: The mean±standard deviation (SD) of the total number of M-LPD TACE per patient was 3.7±1.1. The mean±SD dose of total miriplatin, lipiodol and porous gelatin sponge particles per patient was 303±103 mg, 21±7.3 ml and 84±57 mg, respectively. There were no significant differences in any adverse events between the first and last M-LPD TACE. Conclusion: Repeated M-LPD TACE for HCC is feasible and safe in selected patients.

KW - Hepatocellular carcinoma

KW - Miriplatin

KW - Transarterial chemoembolization

UR - http://www.scopus.com/inward/record.url?scp=85019681771&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85019681771&partnerID=8YFLogxK

U2 - 10.21873/anticanres.11678

DO - 10.21873/anticanres.11678

M3 - Article

C2 - 28551662

AN - SCOPUS:85019681771

SN - 0250-7005

VL - 37

SP - 3183

EP - 3187

JO - Anticancer Research

JF - Anticancer Research

IS - 6

ER -

Feasibility and safety of repeated transarterial chemoembolization using miriplatin-lipiodol suspension for hepatocellular carcinoma

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this